Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a report released on Friday.
The analysts wrote, “We now raise our PT to $175, after: (1) increasing the patisiran probability of success to 97%, and (2) lowering the Alnylam WACC to 8% to reflect further RNAi therapeutics platform de-risking. We now update our Alnylam patient-based and other models to reflect recent positives, while consolidating views from recent Chardan macro research (e.g. on novel lipid-lowering therapies). (See Figures 3-7.) Notably, a near- best-case safety and efficacy profile emerged from the pivotal APOLLO trial (as discussed in our 20 September 2017 research); and, Alnylam proceeded to file patisiran in an expeditious fashion. We thus newly model a 97% probability of success (POS) for patisiran and $1.77 billion in 2030E risk-adjusted franchise sales (patisiran and follow ons). We now increase the POS of givosiran, to 80% ($540 million in 2030E sales) from 40% in our previous model, given the product’s progress ahead of our expectations.””
ALNY has been the topic of several other reports. Credit Suisse Group increased their target price on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an “outperform” rating in a research note on Friday, November 3rd. Piper Jaffray Companies reissued an “overweight” rating and set a $14.71 target price (down from $188.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 2nd. B. Riley assumed coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, November 1st. They set a “buy” rating and a $240.00 price objective on the stock. Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a report on Friday, December 15th. Finally, FBR & Co assumed coverage on shares of Alnylam Pharmaceuticals in a report on Monday, October 30th. They set a “buy” rating and a $150.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and an average target price of $121.20.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). The company had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm’s revenue was up 24.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.21) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals will post -5.29 EPS for the current year.
In related news, Director Dennis A. Ausiello sold 20,000 shares of the stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $130.00, for a total transaction of $2,600,000.00. Following the completion of the transaction, the director now owns 20,000 shares in the company, valued at $2,600,000. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the transaction, the executive vice president now owns 45,201 shares of the company’s stock, valued at approximately $5,490,113.46. The disclosure for this sale can be found here. In the last quarter, insiders sold 274,075 shares of company stock valued at $35,356,089. 4.30% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State of Alaska Department of Revenue bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $800,000. Westpac Banking Corp bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $723,000. Livforsakringsbolaget Skandia Omsesidigt bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $165,000. Schwab Charles Investment Management Inc. grew its position in Alnylam Pharmaceuticals by 7.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 262,416 shares of the biopharmaceutical company’s stock valued at $33,340,000 after buying an additional 17,866 shares during the period. Finally, Gulf International Bank UK Ltd bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $3,792,000. Institutional investors own 88.39% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.